The Human Nose Organoid Respiratory Virus Model: an <i>Ex Vivo</i> Human Challenge Model To Study Respiratory Syncytial Virus (RSV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pathogenesis and Evaluate Therapeutics
Anubama Rajan, Ashley Weaver, Gina M. Aloisio, Joseph Jelinski, Hannah L. Johnson, Susan Venable, Trevor McBride, Letisha Aideyan, Felipe-Andrés Piedra, Xunyan Ye, Ernestina Melicoff, Malli Rama Kanthi Yerramilli, Xi‐Lei Zeng, Michael A. Mancini, Fabio Stossi, Anthony W. Maresso, Shalaka A. Kotkar, Mary K. Estes, Sarah E. Blutt, Vasanthi Avadhanula, Pedro A. Piedra
Abstract
HNO model of RSV infection to test the efficacy of palivizumab, an FDA-approved monoclonal antibody to prevent severe RSV disease in high-risk infants. Our study reports a breakthrough in both the development of a novel nose organoid model and in our understanding of the host cellular response to RSV and SARS-CoV-2 infection.
Topics & Concepts
Respiratory systemVirologyVirusMedicineNoseEx vivoSars virusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CoronavirusPathogenesisOrganoidCoronavirus disease 2019 (COVID-19)ImmunologyBiologyIn vivoPathologyDiseaseInternal medicineInfectious disease (medical specialty)BiotechnologyGeneticsAnatomyRespiratory viral infections researchViral gastroenteritis research and epidemiologyEnergy Harvesting in Wireless Networks